Correction to: Nature Cancer https://doi.org/10.1038/s43018-025-00940-3, published online 18 April 2025.
In the version of the article initially published, due to an error in figure assembly, the sixth mouse in the “19 CAR-NK” (Day 2) images in Fig. 1d was a duplicate of the second mouse in the same group. Additionally, the “18.2 CAR-NK” (Day 37) mouse image was a duplicate of the sixth “18.2 CAR-NK” (Day 30) mouse directly above it. The amended figure with the correct images is now available in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lei, W., Liu, H., Deng, W. et al. Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer 6, 1295 (2025). https://doi.org/10.1038/s43018-025-01026-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s43018-025-01026-w
